哌拉西林钠/他唑巴坦钠治疗肺部感染的临床研究

目的　以亚胺培南 /西司他丁作为对照药物 ,评价哌拉西林钠 /他唑巴坦钠治疗中、重度肺部感染的有效性和安全性。方法　哌拉西林钠 /他唑巴坦钠 3.375 g静脉滴注 ,每 12 h一次 ,或亚胺培南 /西司他丁 0 .5 g静脉滴注 ,每 12 h一次 ,治疗中、重度肺部感染 ,疗程为 7- 14 d。结果　共治疗病人 90例 ,其中试验组 5 8例 ,对照组 32例。哌拉西林钠 /他唑巴坦钠试验组治疗中、重度肺部感染有效率 91.38% ,治愈率 81.0 4 % ,细菌清除率 89.4 6 % ,副作用发生率 3.4 5 % ;亚胺培南 /西司他丁对照组有效率 90 .6 3% ,治愈率 81.2 5 % ,细菌清除率 90 .0 0 % ,副作用发生率 3.13%。两组各率比较差异无显著性 (p>0 .0 5 )。结论　哌拉西林钠 /他唑巴坦钠是一高效、安全广谱抗菌药物 ,对中、重度肺部感染的疗效与亚胺培南 /西司他丁相似 ,两者副作用发生率相近

A clinical study with piperacillin/tazobactam in the treatment of pulmonary infection

Objective Randomized compared with imipenem/cilastatin to evaluate the efficacy and safety of Pipercillin/tazobactam in the treatment of pulmonary infection. Methods Pipercillin/tazobactam 3.375g iv or imipenem/cilastatin 0.5g iv treated moderate and severe pulmonary infection every 12h for 7 14 days.Results The overall patients 90 cases, trial group 58 cases, controls 32 cases. The clinical efficacy rate of piperacillin/tazobactam was 91.38%; the cured rate was 81.04%; the bacterial clearance rate was 89.46%; the adverse reaction rate was 3.45%. the clinical efficacy rate of imipenem/cilastatin was 90.63%; the cured rate was 81.25% ;the bacterial clearance rate was 90.00%; the adverse reaction rate was 3.13%. compared with trial group and controls P>0.05.Conclusion Pipercillin/tazobactam as so as imipenem/cilastatin is efficacy and safety in the treatment of moderate and severe pulmonary infection.